APA

Sweeny D. J., Li W., Clough J., Bhamidipati S., Singh R., Park G., Baluom M., Grossbard E. & Lau D. T. (20101012). Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. : Drug metabolism and disposition: the biological fate of chemicals.

Chicago

Sweeny David J, Li Weiqun, Clough Jeffrey, Bhamidipati Somasekhar, Singh Rajinder, Park Gary, Baluom Muhammad, Grossbard Elliott and Lau David T-W. 20101012. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. : Drug metabolism and disposition: the biological fate of chemicals.

Harvard

Sweeny D. J., Li W., Clough J., Bhamidipati S., Singh R., Park G., Baluom M., Grossbard E. and Lau D. T. (20101012). Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. : Drug metabolism and disposition: the biological fate of chemicals.

MLA

Sweeny David J, Li Weiqun, Clough Jeffrey, Bhamidipati Somasekhar, Singh Rajinder, Park Gary, Baluom Muhammad, Grossbard Elliott and Lau David T-W. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. : Drug metabolism and disposition: the biological fate of chemicals. 20101012.